Improved Metabolic Control in Diabetes, HSP60, and Proinflammatory MediatorsReport as inadecuate

Improved Metabolic Control in Diabetes, HSP60, and Proinflammatory Mediators - Download this document for free, or read online. Document in PDF available to download.

Autoimmune DiseasesVolume 2012 2012, Article ID 346501, 8 pages

Clinical Study

Centro Diabete, ASL RMB-1D, L.go T. Solera n.7, Rome, Italy

St. Mary-s Hospital of Daejeon Catholic University, Clinical Research Institute, Daeheung-dong, Daejeon, Republic of Korea

Cardiovascular Division, Department of Medicine and Department of Medical Pharmacology, UC Davis Health Systems, Sacramento, CA 95817, USA

Received 15 March 2012; Revised 3 May 2012; Accepted 31 May 2012

Academic Editor: Kamal D. Moudgil

Copyright © 2012 Claudio Blasi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The diabetes-atherosclerosis relationship remains to be fully defined. Repeated prolonged hyperglycemia, increased ROS production and endothelial dysfunction are important factors. One theory is that increased blood levels of heat shock protein HSP60 are proinflammatory, through activation of innate immunity, and contribute to the progression of vascular disease. It was hypothesized that improvement of diabetes control in patients presenting with metabolic syndrome would lower HSP60, and anti-HSP60 antibody levels and decrease inflammatory markers. Paired sera of 17 Italian patients, before and after intensive treatment, were assayed for cytokines, HSP60 and anti-HSP60 antibodies. As expected, intensive treatment was associated with a decrease in HgbA1C and BMI . After treatment, there was a significant decrease in IL-6 . HSP60 levels were before treatment , after treatment  ng-mL . Overall HSP60 concentrations were lower than published reports. Anti-HSP60 antibody titers were high and did not decrease with treatment. In conclusion, improvement of diabetic control did not alter HSP60 concentrations or antiHSP60 antibody titers, but led to a reduction of IL-6 levels.

Author: Claudio Blasi, Eunjung Kim, and Anne A. Knowlton



Related documents